Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467514 | 0.88 | RAF1 (0.50) | RAF1BRAFKDM4EGAARAB9A | |
| SCHEMBL1468134 | 0.88 | RAF1 (0.49) | RAF1BRAFKDM4ENPC1RAB9A | |
| SCHEMBL1467015 | 0.88 | RAF1 (0.49) | RAF1BRAFKDRKDM4ERAB9A | |
| SCHEMBL1466471 | 0.88 | RAF1 (0.49) | RAF1BRAFKDRKDM4ERAB9A | |
| SCHEMBL1467260 | 0.88 | RAF1 (0.49) | RAF1BRAFKDM4ENPC1RAB9A | |
| SCHEMBL1467140 | 0.86 | RAF1 (0.48) | RAF1BRAFKDRKDM4ERAB9A | |
| SCHEMBL1467321 | 0.86 | RAF1 (0.48) | RAF1BRAFKDRKDM4ENPC1 | |
| SCHEMBL1469077 | 0.85 | RXFP1 (0.49) | RAF1BRAFMAPT | |
| SCHEMBL1467541 | 0.85 | RAF1 (0.47) | RAF1BRAFKDRKDM4ENPC1 | |
| SCHEMBL1466856 | 0.85 | RAF1 (0.47) | RAF1BRAFKDRKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | claimed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.